Abstract
This article reviews pertinent legislation regulating the safety of probiotics within the European Union (EU). Currently available probiotic organisms and known issues regarding their safety are briefly summarised. While most of the species and genera, particularly lactobacilli and bifidobacteria are apparently safe, certain micro-organisms may be problematic; particularly the enterococci, which are associated with nosocomial infections and harbour transmissible antibiotic resistance determinants. At present, probiotic human foods are not governed under specific EU regulatory frameworks, although the Novel Food Regulation EU 258 / 97, could be relevant in some specific cases. However, microbial feed additives (regulated by Council Directive 70 / 254 / EEC and in accordance with guidelines of the Scientific Committee on Animal Nutrition (SCAN)) are subjected to detailed safety assessment with the intention of ensuring that they are innocuous to target animals, users and consumers. Particular attention is focused on the presence of transmissible antibiotic resistance markers, and to the potential for production of harmful metabolites. The guidelines do not differentiate between species and strains with long histories of safe use and other micro-organisms. This has caused some concern regarding overregulation, if the same principles are to be applied to probiotics or starter cultures intended for human food use. Accordingly, SCAN has launched an initiative towards a “Qualified Perception of Safety” (QPS) concept, which would allow strains with established safety status to enter the market without extensive testing requirements. It is likely that the European Food Safety Authority (EFSA) will play a central role in the regulation of both human and animal probiotics.
Keywords: probiotics, legislation, safety, novel food regulation, feed additives, gras, qps
Current Pharmaceutical Design
Title: Regulating the Safety of Probiotics - The European Approach
Volume: 11 Issue: 1
Author(s): Atte von Wright
Affiliation:
Keywords: probiotics, legislation, safety, novel food regulation, feed additives, gras, qps
Abstract: This article reviews pertinent legislation regulating the safety of probiotics within the European Union (EU). Currently available probiotic organisms and known issues regarding their safety are briefly summarised. While most of the species and genera, particularly lactobacilli and bifidobacteria are apparently safe, certain micro-organisms may be problematic; particularly the enterococci, which are associated with nosocomial infections and harbour transmissible antibiotic resistance determinants. At present, probiotic human foods are not governed under specific EU regulatory frameworks, although the Novel Food Regulation EU 258 / 97, could be relevant in some specific cases. However, microbial feed additives (regulated by Council Directive 70 / 254 / EEC and in accordance with guidelines of the Scientific Committee on Animal Nutrition (SCAN)) are subjected to detailed safety assessment with the intention of ensuring that they are innocuous to target animals, users and consumers. Particular attention is focused on the presence of transmissible antibiotic resistance markers, and to the potential for production of harmful metabolites. The guidelines do not differentiate between species and strains with long histories of safe use and other micro-organisms. This has caused some concern regarding overregulation, if the same principles are to be applied to probiotics or starter cultures intended for human food use. Accordingly, SCAN has launched an initiative towards a “Qualified Perception of Safety” (QPS) concept, which would allow strains with established safety status to enter the market without extensive testing requirements. It is likely that the European Food Safety Authority (EFSA) will play a central role in the regulation of both human and animal probiotics.
Export Options
About this article
Cite this article as:
Wright von Atte, Regulating the Safety of Probiotics - The European Approach, Current Pharmaceutical Design 2005; 11 (1) . https://dx.doi.org/10.2174/1381612053382322
DOI https://dx.doi.org/10.2174/1381612053382322 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens
Current Topics in Medicinal Chemistry Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus
Current Cardiology Reviews Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients
Current Clinical Pharmacology Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Adenotonsillar Disease
Recent Patents on Inflammation & Allergy Drug Discovery 'Mucormycosis': A Fungal Infection Threatening India During COVID-19' - A Review
Anti-Infective Agents Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets A Rare Case of Tricuspid Valve Endocarditis Caused by Enterococcus Gallinarum in a Patient with Recurrent Urinary Tract Infection
Cardiovascular & Hematological Disorders-Drug Targets Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill
Current Respiratory Medicine Reviews Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review
Current Respiratory Medicine Reviews Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews Magnetite Nanoshuttles for Fighting Staphylococcus aureus Infections: A Recent Review
Current Topics in Medicinal Chemistry Stability Assessment of Extemporaneous Formulation of Amoxicillin for Parenteral Antimicrobial Therapy
Current Pharmaceutical Analysis Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Current Drug Metabolism Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa
Current Pharmaceutical Design